Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2022 | Improving the identification of patients with high-risk multiple myeloma

Mehmet Samur • 10 Dec 2022
ASH 2022
Multiple Myeloma

Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, describes the advantages of new technologies and of datasets collected from large cohorts to identify patients with high-risk multiple myeloma more efficiently. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mehmet Samur

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Highlights from a session on advances in myeloma biology at COMy 2025 2:45
Highlights from a session on advances in myeloma biology at COMy 2025
Mehmet Samur • 19 May 2025
The value of whole genome sequencing in multiple myeloma 1:53
The value of whole genome sequencing in multiple myeloma
Mehmet Samur • 19 May 2025
Advancing the understanding of the biology of extramedullary disease in myeloma 2:24
Advancing the understanding of the biology of extramedullary disease in myeloma
Mehmet Samur • 19 May 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals